What counts as high
Two numbers do most of the work, both from the 2022 European Atherosclerosis Society consensus statement, the reference document in this area.
| Level | What it means |
|---|---|
| 50 mg/dL and above | Risk enhancer. Factored into overall cardiovascular risk assessment |
| 180 mg/dL and above | Very high. Lifetime risk comparable to untreated familial hypercholesterolaemia |
Why one test is usually enough
The EAS panel's recommendation is direct: "This panel recommends testing Lp(a) concentration at least once in adults." The reason is that Lp(a) is overwhelmingly genetically determined and does not drift much with diet, weight or the passage of time the way LDL and triglycerides do. Repeat testing rarely changes the picture.
The statement adds that cascade testing, meaning testing blood relatives, has potential value in familial hypercholesterolaemia, or where there is a family or personal history of very high Lp(a) or premature cardiovascular disease. If your own result is high, that is the situation in which your siblings and children may benefit from knowing theirs.
What the evidence actually supports
The consensus statement is unusually clear about where the evidence is strong and where it is not, which is worth reproducing rather than paraphrasing.
Supported. Epidemiologic and genetic studies involving hundreds of thousands of people strongly support a causal and continuous association between Lp(a) concentration and cardiovascular outcomes across different ethnicities. Elevated Lp(a) is a risk factor even at very low levels of LDL cholesterol, which is why it can explain events in people whose standard lipid panel looks reassuring. High Lp(a) is also associated with calcification of the aortic valve.
Not supported. Current findings do not support Lp(a) as a risk factor for venous thrombotic events or impaired fibrinolysis, despite the molecule's structural resemblance to plasminogen. If you have read that Lp(a) causes clots, that is the claim the consensus does not back.
Unsettled. Very low Lp(a) may be associated with an increased risk of diabetes, which the panel flags as meriting further study rather than as established.
What to do about a high result
Nothing on the pharmacy shelf lowers Lp(a) specifically. Statins do not, and the EAS statement's guidance in the absence of a targeted therapy is "early intensive risk factor management, targeted according to global cardiovascular risk and Lp(a) level." In practice that means the things that were always worth doing become more worth doing, and earlier: LDL, blood pressure, smoking, glucose. A high Lp(a) does not have its own treatment, it raises the stakes on everything else.
For the narrow case of very high Lp(a) with cardiovascular disease that keeps progressing despite optimal management, the statement lists lipoprotein apheresis as an option. That is a specialist decision, not a general one.
Sponsored option
Vetted Aug 19, 2026Affiliate link, we may earn a commission at no extra cost to you.
Everlywell Our score 4.0/5
At-home lab tests
Pricing as of Aug 19, 2026
HbA1c $49; cholesterol and lipids $49; heart health panel $99
Where the drug trials stand
The 2022 statement closed by saying that trials of specific Lp(a)-lowering treatments are critical to confirm clinical benefit. Those trials are now well advanced, and as of August 2026 none of the drugs is approved, because regulators want cardiovascular outcome data rather than a demonstration that the number falls.
| Trial | Drug | Participants | Status | Primary completion |
|---|---|---|---|---|
| Lp(a)HORIZON (NCT04023552) | Pelacarsen | 8,323 | Completed | 16 July 2026 |
| OCEAN(a)-Outcomes (NCT05581303) | Olpasiran | 7,297 | Active, not recruiting | 31 March 2028 |
| OCEAN(a)-PreEvent (NCT07136012) | Olpasiran | 11,000 | Recruiting | 20 October 2031 |
The first of those reaching its primary completion date is the thing to watch. A completed primary endpoint is not a published result and is not an approval, and until the outcome data are reported it remains unknown whether lowering Lp(a) lowers events. That is precisely the question the trial exists to answer.
Our Lp(a) reference page lists the thresholds with their source and effective date, and the lab result lookup will place a specific number against them.
Frequently asked questions
What is a normal lipoprotein(a) level?
The EAS consensus treats 50 mg/dL and above as a risk enhancer, and 180 mg/dL and above as very high, with a lifetime cardiovascular risk comparable to untreated familial hypercholesterolaemia. The association is described as causal and continuous, so there is no sharp line below which risk is zero. Check whether your result is in mg/dL or nmol/L before comparing it to anything.
How often should Lp(a) be tested?
The EAS panel recommends testing at least once in adulthood. Levels are largely genetically determined and stable over time, so repeat testing seldom changes the answer. Cascade testing of relatives has potential value in familial hypercholesterolaemia or with a family or personal history of very high Lp(a) or premature cardiovascular disease.
Do statins lower Lp(a)?
No. There is no approved therapy that specifically lowers Lp(a). The EAS guidance in its absence is early, intensive management of the risk factors that can be modified, targeted to your overall cardiovascular risk and your Lp(a) level.
Does high Lp(a) cause blood clots?
The 2022 EAS consensus states that current findings do not support Lp(a) as a risk factor for venous thrombotic events or impaired fibrinolysis. Its established associations are with atherosclerotic cardiovascular disease and with calcification of the aortic valve.
Is there a drug for high Lp(a) yet?
Not as of August 2026. Two large phase 3 cardiovascular outcome programs are running. Lp(a)HORIZON, testing pelacarsen in 8,323 participants, reached its primary completion date on 16 July 2026; OCEAN(a)-Outcomes, testing olpasiran in 7,297 participants, runs to March 2028. Regulators require evidence that events fall, not just that the number falls.
Why is my Lp(a) high when my cholesterol is normal?
Because they are set by different things. Lp(a) is largely inherited and moves little with lifestyle, and the EAS statement notes that elevated Lp(a) remains a risk factor even at very low LDL cholesterol. A normal standard lipid panel does not rule it out, which is the argument for measuring it once.
When to talk with a clinician
Ask for the test once if you have not had it, particularly if you have premature cardiovascular disease in the family, a personal event that your standard lipid panel does not explain, or known familial hypercholesterolaemia. If the result is high, the conversation worth having is not about lowering Lp(a), which is not currently possible, but about how much more aggressively to manage everything else, and whether your relatives should be tested.
